|
|
AS02A |
|
Vaxjo ID |
505 |
|
Vaccine Adjuvant Name |
AS02A |
|
Adjuvant VO ID |
VO_0005359
|
|
Description |
adult formulation of the AS02 vaccine adjuvant |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
Mali |
|
Host Species for Testing |
Human |
|
Components |
An AS02A vaccine adjuvant contains 50 ug MPL and 50ug QS21, 250uL of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 mL. |
|
Dosage |
0.65 to 0.75mL |
|
Function |
Type: combination vaccine adjuvant. Target Receptor: Toll-like receptor 4 (TLR4). |
| References |
NCT00308061: Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in Bandiagara, Mali [https://clinicaltrials.gov/study/NCT00308061]
|
|
